Ecolab Opens New Bioprocessing Lab in Eastern U.S.
The new facility adds to the company’s existing infrastructure and is set to provide comprehensive technical support for bioprocessing to biopharmaceutical companies and contract manufacturers.
Water, hygiene, and infection prevention solutions and services provider, Ecolab, has announced the opening of its new state-of-the-art bioprocessing applications laboratory in King of Prussia, Pa. (1). This facility, which is positioned close to many large pharmaceutical operations in the Eastern U.S., adds to the company’s existing lab in Wales, U.K., and forms part of the Ecolab Life Sciences Pharma Centre of Excellence.
The new facility, which is equipped with high-throughput process development tools and manufacturing scale chromatography columns, will provide comprehensive, turnkey technical support for the purification of biotherapeutic molecules at all scales to biopharmaceutical companies and contract manufacturers. For larger biopharma companies, the applications lab can be used all the way from early to late-stage development, inclusive of the characterization of alternative resins that can help reduce manufacturing costs and support regulatory submissions.
“Our new Bioprocessing Applications Lab marks a significant milestone in our ability to be a global technical partner to our customers around the world,” said Jennifer Sorrells, Ph.D., vice president of research and development, Ecolab Life Sciences, in a company press release about the new lab (1). “This facility demonstrates our commitment to delivering best-in-class bioprocessing solutions by pairing Ecolab’s innovative resin toolbox with deep domain expertise to optimize the purification process. We are dedicated to empowering our customers to accelerate the delivery of life-saving therapies to market.”
The global bioprocessing market, incorporating both large- and small-scale, is expected to experience double digit growth over the next five years, reaching USD 177.8 billion in 2030 (2). This growth will be driven by the rising demand for biopharmaceutical products, which are offering targeted therapeutic options for chronic diseases. Additionally, as a result of the increased demand for biopharmaceuticals, industry is seeing greater investment into technologies that can improve efficiencies in bioprocessing while also maintaining regulatory compliance.
North America commands the largest revenue share of the bioprocessing market (38% in 2024) thanks to the regions focused R&D in biomanufacturing, developed infrastructure, increasing funds for bioprocessing technology, and rising demand for biologics and cell therapies (2). In fact, the U.S. large- and small-scale bioprocessing market alone, which accounts for 34% of the global market, is expected to grow at a compound annual rate of 13.5% over the next five years (3).
Back in 2023, the company announced it was expanding its business through the construction of a new biologics resin manufacturing facility in Landenberg, Pa. (4). This expansion marked the first U.S.-based biologics division for the company (4).
References
Ecolab. Ecolab Life Sciences Opens New State-of-the-Art Bioprocessing Applications Laboratory in Pennsylvania, U.S. Press Release, May 14, 2025.
Grand View Research. Large and Small-scale Bioprocessing Market Size, Share and Trends Analysis Report by Workflow (Downstream, Upstream), by Product, by Use Type, by Mode (In-house, Outsourced), by Region, and Segment Forecasts, 2025–2030. Market Research Report, February 2025.
Grand View Research. U.S. Large and Small-Scale Bioprocessing Market Size and Outlook. Horizon Databook, Market Research Report, 2025.
Ecolab. Purolite Grows Bioprocessing Production Capacity with New U.S. Manufacturing Facility. Press Release, June 6, 2023.